These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

705 related items for PubMed ID: 20098724

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Merozoite Surface Protein 1 from Plasmodium falciparum Is a Major Target of Opsonizing Antibodies in Individuals with Acquired Immunity against Malaria.
    Jäschke A, Coulibaly B, Remarque EJ, Bujard H, Epp C.
    Clin Vaccine Immunol; 2017 Nov; 24(11):. PubMed ID: 28877929
    [Abstract] [Full Text] [Related]

  • 3. Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort.
    Adamou R, Dechavanne C, Sadissou I, d'Almeida T, Bouraima A, Sonon P, Amoussa R, Cottrell G, Le Port A, Theisen M, Remarque EJ, Longacre S, Moutairou K, Massougbodji A, Luty AJF, Nuel G, Migot-Nabias F, Sanni A, Garcia A, Milet J, Courtin D.
    Malar J; 2019 Jun 11; 18(1):194. PubMed ID: 31185998
    [Abstract] [Full Text] [Related]

  • 4. Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children.
    Pinder M, Sutherland CJ, Sisay-Joof F, Ismaili J, McCall MB, Ord R, Hallett R, Holder AA, Milligan P.
    Infect Immun; 2006 May 11; 74(5):2887-93. PubMed ID: 16622227
    [Abstract] [Full Text] [Related]

  • 5. Age-dependent IgG subclass responses to Plasmodium falciparum EBA-175 are differentially associated with incidence of malaria in Mozambican children.
    Dobaño C, Quelhas D, Quintó L, Puyol L, Serra-Casas E, Mayor A, Nhampossa T, Macete E, Aide P, Mandomando I, Sanz S, Puniya SK, Singh B, Gupta P, Bhattacharya A, Chauhan VS, Aponte JJ, Chitnis CE, Alonso PL, Menéndez C.
    Clin Vaccine Immunol; 2012 Feb 11; 19(2):157-66. PubMed ID: 22169088
    [Abstract] [Full Text] [Related]

  • 6. Antibody Correlates of Protection from Clinical Plasmodium falciparum Malaria in an Area of Low and Unstable Malaria Transmission.
    Hamre KES, Ondigo BN, Hodges JS, Dutta S, Theisen M, Ayodo G, John CC.
    Am J Trop Med Hyg; 2020 Dec 11; 103(6):2174-2182. PubMed ID: 33124533
    [Abstract] [Full Text] [Related]

  • 7. Association of antibodies to Plasmodium falciparum merozoite surface protein-4 with protection against clinical malaria.
    Perraut R, Varela ML, Joos C, Diouf B, Sokhna C, Mbengue B, Tall A, Loucoubar C, Touré A, Mercereau-Puijalon O.
    Vaccine; 2017 Dec 04; 35(48 Pt B):6720-6726. PubMed ID: 29042203
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM, Miura K, Sullivan J, Long CA, Barnwell JW.
    Malar J; 2016 Mar 15; 15():159. PubMed ID: 26975721
    [Abstract] [Full Text] [Related]

  • 10. Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness.
    Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, Schoepflin S, Gilson PR, Murphy VJ, Anders RF, Mueller I, Beeson JG.
    Infect Immun; 2009 Mar 15; 77(3):1165-74. PubMed ID: 19139189
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Humoral immune response to Plasmodium falciparum vaccine candidate GMZ2 and its components in populations naturally exposed to seasonal malaria in Ethiopia.
    Mamo H, Esen M, Ajua A, Theisen M, Mordmüller B, Petros B.
    Malar J; 2013 Feb 05; 12():51. PubMed ID: 23383869
    [Abstract] [Full Text] [Related]

  • 13. Breadth of Functional Antibodies Is Associated With Plasmodium falciparum Merozoite Phagocytosis and Protection Against Febrile Malaria.
    Kana IH, Singh SK, Garcia-Senosiain A, Dodoo D, Singh S, Adu B, Theisen M.
    J Infect Dis; 2019 Jun 19; 220(2):275-284. PubMed ID: 30820557
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Assessment of the role of naturally acquired antibody levels to Plasmodium falciparum merozoite surface protein-1 in protecting Papua New Guinean children from malaria morbidity.
    al-Yaman F, Genton B, Kramer KJ, Chang SP, Hui GS, Baisor M, Alpers MP.
    Am J Trop Med Hyg; 1996 May 19; 54(5):443-8. PubMed ID: 8644896
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein.
    Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P.
    Infect Immun; 2004 Jan 19; 72(1):247-52. PubMed ID: 14688102
    [Abstract] [Full Text] [Related]

  • 19. Antibodies against a Plasmodium falciparum RON12 inhibit merozoite invasion into erythrocytes.
    Ito D, Takashima E, Yamasaki T, Hatano S, Hasegawa T, Miura K, Morita M, Thongkukiatkul A, Diakite M, Long CA, Sattabongkot J, Udomsangpetch R, Iriko H, Ishino T, Tsuboi T.
    Parasitol Int; 2019 Feb 19; 68(1):87-91. PubMed ID: 30342119
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.